The company said that the program can help users confirm their insurance benefits and obtain pre-authorization before sensor placement. The Eversense Bridge Program is also meant to help healthcare providers and patients appeal to insurers regarding denied claims.
Senseonics’ Eversense system is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.
“The Eversense Bridge Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” president & CEO Tim Goodnow said in prepared remarks.
“Insurance companies unfamiliar with the newest approved diabetes technology may deny coverage for a wide range of insured patients who have come forward demanding this technology. We developed this program to reduce barriers for patients who seek access to this technology right away. Every patient who qualifies for the program will now have improved access to this innovative diabetes management technology,” he added.
In November, the FDA expanded approval for the Eversense device, giving nurse practitioners and physician assistants the ability to implant and remove the CGM.
And earlier this year, Senseonics touted that its Eversense XL 180-day CGM was implanted into the first participant of a trial designed to support a pre-market application to the FDA.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.